Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SALT LAKE CITY, AUG. 19, 2026 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, ANNOUNCED TODAY THAT SCOTT GLEASON HAS BEEN APPOINTED CHIEF FINANCIAL OFFICER (CFO), EFFECTIVE AUGUST 31, 2026. MR. GLEASON BRINGS MORE THAN 25 YEARS OF HEALTHCARE, DIAGNOSTICS, AND CAPITAL MARKETS EXPERIENCE TO SERA.

SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

SALT LAKE CITY, AUG. 12, 2026 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026. KEY SECOND QUARTER AND RECENT HIGHLIGHTS: ADVANCED COMMERCIAL ADOPTION STRATEGY WITH FOURTH PARTNERSHIP PROGRAM LAUNCH:IN AUGUST 2026, WE LAUNCHED FOURTH PARTNERSHIP PROGRAM, EXPANDING IMPLEMENTATION OF PRETRM TEST-GUIDED CARE THROUGH A STATE-BASED INITIATIVE WITH A NATIONAL PAYER.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

SALT LAKE CITY, JULY 29, 2026 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED IT WILL REPORT SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON WEDNESDAY AUGUST 12, 2026, AFTER THE CLOSE OF THE MARKET. THE COMPANY WILL HOST A CORRESPONDING CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS OPERATIONAL HIGHLIGHTS, FINANCIAL RESULTS AND KEY TOPICS AT5:00 P.M.

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

-- STUDY HIGHLIGHTS SCREENING EFFICIENCY AND POTENTIAL COST SAVINGS IN A LARGE UNDERSERVED POPULATION -- SALT LAKE CITY, JULY 9, 2026 /PRNEWSWIRE/ --SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION, TODAY ANNOUNCED PUBLICATION OF A NEW SUBGROUP ANALYSIS FROM THE PRIME RANDOMIZED CONTROLLED TRIAL. THE ANALYSIS DEMONSTRATED THAT PRETRM TEST-GUIDED CARE IN FIRST-TIME PREGNANCIES SIGNIFICANTLY IMPROVED NEONATAL OUTCOMES, INCLUDING A 22% REDUCTION IN NEONATAL INTENSIVE CARE UNIT (NICU) ADMISSIONS.

PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PRETRM TEST-GUIDED CARE

SALT LAKE CITY, JUNE 30, 2026 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED THAT MARK CAPONE WILL JOIN ITS BOARD OF DIRECTORS, EFFECTIVE JULY 1, 2026. MR. CAPONE IS A SEASONED HEALTHCARE EXECUTIVE WITH MORE THAN 40 YEARS OF LEADERSHIP EXPERIENCE ACROSS THE DIAGNOSTICS AND LIFE SCIENCES SECTORS, INCLUDING EXTENSIVE SERVICE ON PRIVATE AND PUBLIC COMPANY BOARDS AND COMMITTEES.

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

SALT LAKE CITY, JUNE 24, 2026 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION, TODAY ANNOUNCED ITS PARTICIPATION IN A MULTI-INSTITUTIONAL RESEARCH PROGRAM THAT WAS AWARDED UP TO $10.4 MILLION BY THE ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H) TO DEVELOP A NOVEL POINT-OF-CARE DIAGNOSTIC TEST DESIGNED TO IMPROVE THE SAFETY OF LABOR AND DELIVERY. THE AWARD, PART OF ARPA-H'S MAKING OBSTETRICS CARE SMART (MOCS) PROGRAM, SUPPORTS A COLLABORATION LED BY RESEARCHERS AT THE UNIVERSITY OF CALIFORNIA SAN DIEGO (UC SAN DIEGO), ALONGSIDE SERA PROGNOSTICS AND ALLEGRO MICROSYSTEMS.

SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH

--ALIGNS WITH GROWING FOCUS ON EARLY IDENTIFICATION AND MANAGEMENT OF PRETERM BIRTH RISK-- SALT LAKE CITY, JUNE 23, 2026 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION, TODAY ACKNOWLEDGED RECENT LEGISLATIVE ACTION IN ILLINOIS AIMED AT EXPANDING ACCESS TO EVIDENCE-BASED APPROACHES FOR IDENTIFYING AND MANAGING THE RISK OF PRETERM BIRTH AMONG PREGNANT INDIVIDUALS. THE LEGISLATION AMENDS THE ILLINOIS PUBLIC AID CODE TO REQUIRE THE STATE'S MEDICAL ASSISTANCE PROGRAM (MEDICAID) TO PROVIDE COVERAGE AND REIMBURSEMENT FOR PRESCRIBED PROTEOMIC BLOOD TESTS THAT ARE USED TO IDENTIFY AND MANAGE THE RISK OF SPONTANEOUS PRETERM BIRTH.

SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

SALT LAKE CITY, JUNE 1, 2026 /PRNEWSWIRE/ --SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED THAT JEFF ELLIOTT HAS NOTIFIED THE COMPANY OF HIS INTENTION TO STEP DOWN FROM ITS BOARD OF DIRECTORS, EFFECTIVE JUNE 4, 2026, AND THAT HE WILL NOT STAND FOR RE-ELECTION AT THE COMPANY'S UPCOMING ANNUAL MEETING OF SHAREHOLDERS. MR. ELLIOTT HAS SERVED ON SERA'S BOARD SINCE MARCH 2025, PROVIDING STRATEGIC GUIDANCE AND LEADERSHIP DURING A PERIOD OF GROWTH AND DEVELOPMENT FOR THE COMPANY.

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

SALT LAKE CITY, MAY 6, 2026 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. KEY FIRST QUARTER AND RECENT HIGHLIGHTS: PUBLISHED LANDMARK PRIME RANDOMIZED TRIAL: STUDY IN 5,018 WOMEN SHOWING THE PRETRM TEST REDUCED EARLY PRETERM BIRTHS (56%

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SALT LAKE CITY, APRIL 22, 2026 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED IT WILL REPORT FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON WEDNESDAY MAY 6, 2026, AFTER THE CLOSE OF THE MARKET. THE COMPANY WILL HOST A CORRESPONDING CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS OPERATIONAL HIGHLIGHTS, FINANCIAL RESULTS AND KEY TOPICS AT5:00 P.M.

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

SALT LAKE CITY, MARCH 18, 2026 /PRNEWSWIRE/ --SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025. KEY 2025 AND RECENT HIGHLIGHTS: DATA GENERATION PUBLISHED LANDMARK PRIME STUDY DEMONSTRATING PRETRM BLOOD TEST REDUCES EARLIEST PRETERM BIRTHS AND NEWBORN COMPLICATIONS: IN JANUARY 2026, THE PRIME STUDY, A RANDOMIZED CONTROLLED TRIAL OF 5,018 WOMEN, WAS PUBLISHED IN PREGNANCY, THE PEER-REVIEWED JOURNAL OF THE SOCIETY FOR MATERNAL-FETAL MEDICINE.

Sera Prognostics, Inc.

SERA

Price

Financial Reports

No items found.

Press Releases

Sera Prognostics, Inc.

SERA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SERA